Intern Med J . Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2

[tetano]

Intern Med J


. 2022 Nov 27.
doi: 10.1111/imj.15954. Online ahead of print.
Low mortality in vaccinated immunocompromised haematology patients infected with SARS-CoV-2


Briony Shaw ^{1 2} , Jake Shortt ^{1 2} , Michael Low ^{1 2} , Benjamin Rogers ^{1 3} , Zane Kaplan ^{1 2} , Pasquale Fedele ^{1 2} , Gareth Gregory ^{1 2} , Shahla Vilcassim ^{1 2} , Michael Gilbertson ^{1 2} , George Grigoriadis ^{1 2} , Stephen Opat ^{1 2}



Affiliations

• PMID: 36436197
• DOI: 10.1111/imj.15954

Abstract

Coronavirus disease 2019 (COVID-19) infection in patients with haematological neoplasms has been associated with increased mortality; however, many studies in this patient group were reported early in the pandemic. The authors evaluated outcomes of COVID-19 infection in patients with haematological conditions following widespread vaccination, newer viral variants and increasingly effective antiviral therapies. A 4% mortality rate was found and contemporary risk factors for hospitalisation including older age, nonvaccination or partial COVID-19 vaccination status and infection with non-Omicron strain were identified.

Keywords: COVID-19; cancer; haematological malignancy; haematological neoplasm; vaccination.